$1.30
7.44% yesterday
Nasdaq, Nov 25, 09:50 pm CET
ISIN
US15673T1007
Symbol
IPSC

Century Therapeutics Inc Stock price

$1.30
-0.09 6.47% 1M
-1.74 57.24% 6M
-2.02 60.84% YTD
-0.14 9.72% 1Y
-16.65 92.76% 3Y
-21.53 94.31% 5Y
-21.53 94.31% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
+0.09 7.44%
ISIN
US15673T1007
Symbol
IPSC
Sector
Industry

Key metrics

Market capitalization $110.54m
Enterprise Value $-32.97m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.29
EV/Sales (TTM) EV/Sales -12.26
P/S ratio (TTM) P/S ratio 41.09
P/B ratio (TTM) P/B ratio 0.56
Revenue growth (TTM) Revenue growth 7.92%
Revenue (TTM) Revenue $2.69m
EBIT (operating result TTM) EBIT $-132.58m
Free Cash Flow (TTM) Free Cash Flow $-113.12m
Cash position $198.11m
EPS (TTM) EPS $-1.86
P/E forward negative
P/S forward 35.01
EV/Sales forward negative
Short interest 5.09%
Show more

Is Century Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Century Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Century Therapeutics Inc forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a Century Therapeutics Inc forecast:

Buy
86%
Hold
14%

Financial data from Century Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
2.69 2.69
8% 8%
100%
- Direct Costs 14 14
39% 39%
503%
-11 -11
49% 49%
-403%
- Selling and Administrative Expenses 18 18
21% 21%
670%
- Research and Development Expense 90 90
6% 6%
3,352%
-119 -119
1% 1%
-4,425%
- Depreciation and Amortization 14 14
39% 39%
503%
EBIT (Operating Income) EBIT -133 -133
4% 4%
-4,929%
Net Profit -130 -130
1% 1%
-4,829%

In millions USD.

Don't miss a Thing! We will send you all news about Century Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Century Therapeutics Inc Stock News

Neutral
GlobeNewsWire
about one hour ago
PHILADELPHIA, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and autoimmune disease, today announced that members of the management team will participate in the following events at the Piper Sandler 36th Annual Healthcare Conference on Wednesday, ...
Neutral
GlobeNewsWire
21 days ago
– Expansion of Phase 1 CALiPSO-1 trial of CNTY-101 in autoimmune disease to include diffuse cutaneous systemic sclerosis and idiopathic inflammatory myopathy –
Neutral
GlobeNewsWire
22 days ago
PHILADELPHIA, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and autoimmune disease, today announced that Brent Pfeiffenberger, Pharm.D., Chief Executive Officer, and Chad Cowan, Ph.D., Chief Scientific Officer, will participate in a fireside chat...
More Century Therapeutics Inc News

Company Profile

Century Therapeutics, Inc. engages in the development of off-the-shelf cell therapies to advance the course of cancer care. It engages in harnessing the power of adult stem cells to develop curative allogeneic cell therapies for cancer. The company was founded by Marcela Maus and Hiromitsu Nakauchi in 2018 and is headquartered in Philadelphia, PA.

Head office United States
CEO Brent Pfeiffenberger
Employees 165
Founded 2018
Website www.centurytx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today